Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, IDT Ally to Offer Oligo Synthesis Services to Pharmas

NEW YORK (GenomeWeb News) - Agilent Technologies and Integrated DNA Technologies will jointly offer oligo synthesis and other products and services to create a "complete development pathway" for drug developers, the companies said yesterday.
The companies said they will provide reciprocal referrals for synthetic oligonucleotides and will offer chemical and analytical services designed to help customers reduce time and costs associated with moving from research to clinical development.
Under the agreement, IDT will produce small-scale and mid-scale products for use in research and drug screening, while Agilent's Nucleic Acid Solutions division will contribute large-scale quantities of oligos to be used as active pharmaceutical ingredients in clinical trials and drug manufacturing.
IDT's COO, Trey Martin, said the agreement allows the companies to offer "a bench-to-bedside oligonucleotide manufacturing package," that includes "harmonized manufacturing methods from basic research scales through API manufacturing."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.